The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...

In the open-label FIBROMET trial, metformin treatment was associated with reductions in bone marrow fibrosis and downregulation of key oncogenic signaling pathways in patients wit ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain: Wonderful.

The researchers identified 411 patients with PMF who had baseline basophil and eosinophil counts available at the time of diagnosis or first referral. After a median follow-up of 52 months, most ...

Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation can make your body produce too many blood cells.  JAK2 ...

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment. Responses to treatment with Jakafi (ruxolitinib) were ...

Pelabresib and Rituxan combination showed superior spleen volume reduction and symptom score improvement compared to placebo in myelofibrosis patients. Hemoglobin response and bone marrow fibrosis ...

Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) ...

(a)-(d): The bone marrow biopsy shows mild hypercellularity (a, H&E 200×) and mild to moderate fibrosis (b, Reticulin stain, 200×). CD79a (c, 200×) and CD3 (d, 200×) immunostains highlight lymphoid ...